

## Special Issue

# 10th Anniversary of Biomedicines—Advances in Mesenchymal Stem Cells

### Message from the Guest Editors

The year 2023 marks the 10th anniversary of *Biomedicines*, a peer-reviewed, open-access journal in the biomedical field. So far, *Biomedicines* has published more than 2700 papers from more than 17,000 authors. We appreciate each author, reviewer, and academic editor whose support has brought us to where we are today. To celebrate this significant milestone, we aim to publish a Special Issue entitled 10th Anniversary of *Biomedicines*—Advances in Mesenchymal Stem Cells. Mesenchymal stem cells (MSCs) represent a promising candidate source for cell therapies due to their effects on tissue and organ homeostasis; revascularization and tissue repair; as well as their immunomodulatory, anti-inflammatory, pro-angiogenic, pleiotropic, and tropic abilities. For this reason, considerable efforts have been made to introduce advanced MSCs-based therapy into clinical practice. This Special Issue is seeking to collect the latest innovative findings and achievements in the field of MSCs-based therapy.

### Guest Editors

Prof. Dr. Simona Delle Monache

Department of Biotechnological and Applied Clinical Sciences,  
University of L'Aquila, 67100 L'Aquila, Italy

Dr. Vincenzo Mattei

Laboratory of Experimental Medicine and Environmental Pathology,  
Rieti, Italy

### Deadline for manuscript submissions

closed (31 May 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/106664](https://mdpi.com/si/106664)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).